9th Mar 2021 14:18
Shield Therapeutics PLC - commercial stage pharmaceutical company - notes that Australia's Therapeutics Goods Administration has approved Feraccru to treat iron deficiency with or without anaemia in adults. Feraccru is already approved in the UK, EU, Switzerland and US. Norgine Pty Ltd will lead all marketing activities in Australia, Shield Therapeutics noted.
Current stock price: 38.95 pence, down 0.8% on Tuesday
Year-to-date change: down 37%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Shield Thera